ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

Rauscher Tabs Oak Ridge Immunologists To Head Basic Research At Frederick

August 30, 1974

In Brief: D. Gary Gilliland Named President and Director of Fred Hutchinson Cancer Research Center

November 21, 2014

Interim Results Show Vaccine Lowers Breast Cancer Recurrence

December 30, 2011

Obama’s First Budget Proposes $6 Billion For Cancer Research As Step To Doubling

February 27, 2009

NCI to Undergo More GAO Probes

July 15, 1977

In Brief: Greenwald Reorganizing DCPC, Elevates Surveillance to Program, Moves Branches

February 3, 1989